Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | SLC34A1 | Q06495 | 1/20 | 0.46 |
| ▸ | FDPS | P14324 | 2/20 | 0.42 |
| ▸ | BLM | P54132 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MMP2 | P08253 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | TYMS | P04818 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | PGK1 | P00558 | 1/20 | 0.31 |
| ▸ | PGK2 | P07205 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphoric Acid SCHEMBL3781492 | 1.00 | CA2 (0.50) | CA2SLC34A1FDPSBLMTDP1 | |
| Phosphoric Acid SCHEMBL11036897 | 1.00 | CA2 (0.50) | CA2SLC34A1FDPSBLMTDP1 | |
| Phosphoric Acid SCHEMBL11651209 | 1.00 | CA2 (0.50) | CA2SLC34A1FDPSBLMTDP1 | |
| Phosphoric Acid SCHEMBL5449618 | 1.00 | CA2 (0.50) | CA2SLC34A1FDPSBLMTDP1 | |
| Phosphoric Acid SCHEMBL8852334 | 1.00 | CA2 (0.50) | CA2SLC34A1FDPSBLMTDP1 | |
| Phosphoric Acid SCHEMBL22117087 | 1.00 | CA2 (0.50) | CA2SLC34A1FDPSBLMTDP1 | |
| Phosphoric Acid SCHEMBL9701339 | 1.00 | CA2 (0.50) | CA2SLC34A1FDPSBLMTDP1 | |
| Phosphoric Acid SCHEMBL1018169 | 1.00 | — | — | |
| Phosphoric Acid SCHEMBL21569209 | 1.00 | CA2 (0.50) | CA2SLC34A1FDPSBLMTDP1 | |
| Phosphoric Acid SCHEMBL10585058 | 1.00 | CA2 (0.50) | CA2SLC34A1FDPSBLMTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 782 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4743599-A1 | METHOD FOR PURIFYING A FILTRATE FROM LEACHING OF BLACK MASS FROM SPENT LITHIUM-ION BATTERIES | Eramet (FR) | 2026-05-20 | — | — | EP | claimed |
| CN-122070150-A | Composition containing BMP-2, and preparation method and application thereof | 杭州九源基因生物医药股份有限公司 | 2026-05-19 | — | — | CN | claimed |
| US-20260014404-A1 | LONG-TERM FIRE RETARDANT WITH CORROSION INHIBITORS AND METHODS FOR MAKING AND USING SAME | PERIMETER SOLUTIONS, LP (US) | 2026-01-15 | — | — | US | claimed |
| EP-4642246-A2 | METHODS AND SYSTEMS FOR INDUCING COALESCENCE OF FUNGAL PROTEINS, AND FUNGAL FOOD PRODUCTS MADE THEREBY | The Fynder Group, Inc. (US) | 2025-11-05 | — | — | EP | claimed |
| EP-4221771-B1 | INJECTABLE CALCIUM PHOSPHATE-BASED BONE GRAFT COMPOSITION HAVING HIGH ELASTICITY | CG BIO CO LTD (KR) | 2025-10-08 | — | — | EP | claimed |
| WO-2025097045-A1 | COLLOIDAL FOOD BASE COMPOSITIONS COMPRISING MYCELIAL BIOMASS | THE FYNDER GROUP, INC (US) | 2025-05-08 | — | — | WO | claimed |
| US-20250135254-A1 | LONG-TERM FIRE RETARDANT WITH CORROSION INHIBITORS AND METHODS FOR MAKING AND USING SAME | FRS GROUP, LLC (US) | 2025-05-01 | — | — | US | claimed |
| US-12214236-B2 | Long-term fire retardant with corrosion inhibitors and methods for making and using same | FRS GROUP, LLC (US) | 2025-02-04 | — | — | US | claimed |
| US-12214237-B2 | Long-term fire retardant with corrosion inhibitors and methods for making and using same | FRS GROUP, LLC (US) | 2025-02-04 | — | — | US | claimed |
| WO-2025012580-A1 | METHOD FOR PURIFYING A FILTRATE FROM LEACHING OF BLACK MASS FROM SPENT LITHIUM-ION BATTERIES | ERAMET (FR) | 2025-01-16 | — | — | WO | claimed |
| WO-2010129819-A2 | DERMAL DELIVERY COMPOSITIONS COMPRISING ACTIVE AGENT-CALCIUM PHOSPHATE PARTICLE COMPLEXES AND METHODS OF USING THE SAME | LABORATORY SKIN CARE, INC. (US) | 2010-11-11 | — | — | WO | claimed |
| JP-4260880-B2 | — | — | 2009-04-30 | — | — | JP | claimed |
| EP-1787954-A2 | Bone substitution material and a method of the manufacture | ETEX CORPORATION (US) | 2007-05-23 | — | — | EP | claimed |
| EP-1521531-A2 | DOUGH COMPOSITION AND METHOD FOR MAKING TORTILLAS | Innophos, Inc. (US) | 2005-04-13 | — | — | EP | claimed |
| US-20040071854-A1 | Dough composition and method for making tortillas | WELLS FARGO BANK, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT | 2004-04-15 | — | — | US | claimed |
| WO-2003103403-A2 | DOUGH COMPOSITION AND METHOD FOR MAKING TORTILLAS | RHODIA INC. (US) | 2003-12-18 | — | — | WO | claimed |
| US-6117456-A | A REACTIVE AMORPHOUS CALCIUM PHOSPHATE MATERIAL HAVING AT LEAST 90% PERCENT AMORPHOUS CHARACTER, AND WHEN PREPARED 1:1 AS A MIXTURE WITH DICALCIUM DIPHOSPHATE IN WATER, THE MIXTURE REMAINS INJECTABLE AND FORMABLE FOR 60 MINUTES | ETEX CORPORATION (US) | 2000-09-12 | — | — | US | claimed |
| EP-0688202-B1 | CALCIUM PHOSPHATE HYDROXYAPATITE PRECURSOR AND METHODS FOR MAKING AND USING THE SAME | AMERICAN DENTAL ASS (US) | 1999-08-18 | — | — | EP | claimed |
| EP-0825963-A1 | BONE SUBSTITUTION MATERIAL AND A METHOD OF ITS MANUFACTURE | ETEX CORPORATION (US) | 1998-03-04 | — | — | EP | claimed |
| WO-1996036562-A1 | BONE SUBSTITUTION MATERIAL AND A METHOD OF ITS MANUFACTURE | ETEX CORPORATION (US) | 1996-11-21 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260014404-A1 | LONG-TERM FIRE RETARDANT WITH CORROSION INHIBITORS AND METHODS FOR MAKING AND USING SAME | SLC6A12, SLC11A2, KCNN1 | CA2 23/4885SLC34A1 31/4885FDPS 2024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.